Get notified when DNTH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Material Weakness (removed) — Previously disclosed material weaknesses in internal controls over financial reporting were fully remediated as of December 31, 2024 and no longer appear in current filing.
Dianthus reports positive Phase 2 gMG data, early CIDP GO, in-licenses DNTH212; loss doubles to $162M
Filed March 9, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 11, 2025 · ~2 min read
Key Changes
-
high
Phase 2 gMG trial met primary endpoints with statistical significance; Phase 3 trial planned mid-2026 with results expected second half 2028. Phase 3 CIDP trial achieved early GO decision with 20 responders before planned 40-patient interim analysis.
Business: Phase 2 gMG results, Phase 3 CIDP GO verify on EDGAR → -
high
In-licensed DNTH212, a bifunctional fusion protein targeting autoimmune pathways, for $30M upfront plus up to $962M in milestones and royalties. Phase 1 trial initiated December 2025 in China.
Business: DNTH212 in-license verify on EDGAR → -
high
Net loss nearly doubled from $85M to $162M driven by $30M DNTH212 payment and 75% increase in R&D spending. September 2025 public offering raised $272M net, extending cash runway into 2028.
MD&A: Financial results and capital raise verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.
Partner
Trade DNTH commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify